Skip to main content
. 2020 Apr;8(7):499. doi: 10.21037/atm.2020.03.194

Figure 2.

Figure 2

Transformation of precision medicine patterns for TNBC. This figure shows the evolution of precision treatment paradigm for TNBCs from biomarker-based targeted therapy to subtyping-based targeted therapy. The subtyping-based paradigm provides deeper insight to the molecular essence of patient tumors and contributes to more efficient target identification and drug development. TNBC, triple-negative breast cancer; HRD, homologous recombination deficiency; PD-1, programmed Cell Death 1; PD-1, programmed Cell Death ligand 1; AR, androgen receptor.